(Q37439884)

20 August 2017

1 reference

title

Newer antiretroviral agents and how to use them (English)

1 reference

20 August 2017

main subject

anti-retroviral agent

0 references

author name string

Holly H Kim

series ordinal

1

1 reference

20 August 2017

Eric S Daar

series ordinal

2

1 reference

20 August 2017

publication date

1 May 2009

1 reference

20 August 2017

published in

Current HIV/AIDS reports

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

55-62

1 reference

https://scigraph.springernature.com/pub.10.1007/s11904-009-0009-9

20 August 2017

exact match

0 references

cites work

Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

1 reference

12 December 2020

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

12 December 2020

Baseline HIV type 1 coreceptor tropism predicts disease progression

1 reference

12 December 2020

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

1 reference

12 December 2020

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis

1 reference

12 December 2020

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

12 December 2020

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

12 December 2020

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

12 December 2020

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

12 December 2020

Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study

1 reference

12 December 2020

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia

1 reference

12 December 2020

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients

1 reference

12 December 2020

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

12 December 2020

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

12 December 2020

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

12 December 2020

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

12 December 2020

Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings

1 reference

12 December 2020

10.1007/S11904-009-0009-9

Identifiers

DOI

1 reference

20 August 2017

1 reference